Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Big Pharma walks away from gene-therapy biotech

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 04, 2023 8:12pm

226 Views

Post# 35479578

RE:RE:RE:Big Pharma walks away from gene-therapy biotech

And just to remind the readers here .. "In December 2022 Quentin30 posted the following " My point is, whilst we wait for more Phase II data, the field is moving... away from chemo + Pela + CPI, to Gene edited cures. What do you think the better investment is ?" The response to Quentin's question became very evident then and even more evident today with Takeda walking away from it gene therapy investments....."

So take Quentin30's posts for the lack of value they represent ...

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China